We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
TWATCHER-Not suggesting its a UK strategy we have more than enough vaccine on order to vaccinate the population several times over. Maybe an option for the countries where COVAX are aiming to supply. There is not enough vaccine to go around in these countries. We know that UK government policy moves with science. Hence why we have the 12 week interval between AZ doses and the data in the over 65s from Scotland that has pushed the EU to reconsider . Anyway I will leave you to it. I'm not sure engaging on LSE with your type is probably worth the time or energy.
Agree with you there twatcher.
Some people believe the 2nd dose is a booster when in reality 2 doses is required to be fully vaccinated.
Whats that got to do with anything? If its a 1 dose regime its 1 dose, you don't need a test to see if you can "get away" with one dose. If it's a 2 dose regime its 2 doses, there is no option to allow some people to "get away" with one dose via an antibody test.
What you posted was garbage.
TWATCHER-J&J is a single dose option. The AZ, Moderna and Pfizer trials were two dose approaches in COVID naive population. The question that needs to be answered is do you need two doses in a prior COVID patient who already has measurable levels of antibodies? This is being looked at. I imagine in populations where vaccine rationing is taking place it will be a possible option to look at with hopefully antibody tests to show this.
Not bitter at all MIDODX, this share has done very well for me i have made my money here and continue to hold and wait for the bigger gains with my free shares. And if you were a bit more patient maybe you could do the same.
Trickymatters that is interesting. perhaps there is a model where you would have to send off a sample for a lab based quantitative test before you travel. With ELISA i would expect turnaround time to be 3-5 days to result depending upon postage and potential backlog at the facility. I think this contract is an exciting development either way as ELISA gives you that quantitative result.
what world are you living in, uk gov is not suggesting that ANYONE only gets a single injection of a 2 jab vaccine process ?, in fact quite the contrary, even though there is data indicating that the first injection is giving brilliant protection.
The antibody test makes sense for those who have had covid they can get away with just one vaccine rather than two doses.
"Mik you D.k. contract was agreed an announced on 11 Feb. Details are announced within 30 days. That's by end of next week. Absolute idiot"
It's actually 20 days (it's only 30 days if it was a competitive tender with a standstill period). If the contract was awarded on 11 February (I believe it may have actually been 9 February) then the notice is due by tomorrow.
That said, despite the GLP court case, the DHSC is still publishing Contract Award Notice late and incomplete. I wouldn't read anything into a CAN not be published this week.
Tecbadger, I read in the Guardian yesterday that the vaccine passports might also recognise antibody status so I think airports will be a context for antibody testing going forward. If you have had the vaccine a double check with an antibody test will establish that your vaccine has kicked in for each traveller. An antigen test shows you have it or you don't at any one time. You could get it on the plane. An antibody test confirms your vaccine efficacy at the time of travelling. International travel is going to be a space for a determined level of risk management in a post lockdown world. We aren't going to be complacent in a world with constant mutations. The whole world will want to ensure this never happens again on this kind of damaging scale.
scoobie123 - You sound very bitter and salty that I sold at £1.15, have you tried yoga?
Mik. You're becoming childish as well as a complete idiot. Off to green bin
Chuggley - Didn't mummy tell you not to lie? Only a blind fool would believe you.
the antibody LFT contract is dead in the water, as I have suggested here for literally months, and was always way over hyped by those that were ramping the bejeeezes out of odx. Not only that, but it's now 2 weeks since the "unshackling" day of the 15th of feb, when the gov contract ended. Some were promoting endlessly drivel here that post 15th feb, RTC and hence ODX would announced multiple orders that they had pre-orders for and were prohibited from fulfilling due to the DHSC contract. So far, not one order noted by either abingdon or ODX.
so I don't know why you are only smelling the coffee now.
The bit of informational news that odx announced today has zero to do with any on that.
Trickymatters - You will never, ever be able to keep up with my trade dealings, so stop trying.
MIKODX the government order with Abingdon health for the ABC-19 worth £1 million. The £75 million maximum potential contract with them for ABC-19 expired after pressure from the good law project on government procurement processes. Nothing to do with the product or the company.
We all know there is a new procurement system in place for purchasing and await to see what happens in this area. Omega have also signed a government contract to manufacture ANY test recommended by Porton Down in the antigen space. We await much newsflow here.
Please stop presenting half messages as truths its very transparent to LTH here.
Mik you D.k. contract was agreed an announced on 11 Feb. Details are announced within 30 days. That's by end of next week. Absolute idiot
Investors here actually thought this was going to go the same way as NCYT, wonder what their thoughts are now?
Mikodox told us ages ago he sold in the 70s. Sigh. He's turning into a complete fantasist. We should just ignore the derampers. Engage in their argument if you feel like it but don't reply directly to them. Better to just focus on the opportunity here which is fabulous.
Folks like FourfigureBS, Twatter, Merchant, Wallbrooke, whothehellamI, instead of spinning false narratives and throwing smoke bombs, why not address the elephant in the room. Tell the good people on here what you think has happened to the UK govt contract and if it even still exists, after all that is why a lot are invested here.
I cant see a use case for the Elisa antibody for airport testing unfortunately. I feel this will always be antigen since its possible to both carry antibodies and the virus (whether at a viral load to be infectious remains to be seen)
Regular antibody testing could be used for applications like maintenance of COVID passports if they become a thing. the good thing about ELISA is it can be quantitative and so a rough assessment of immunity strength can be determined so long as there is a reliable scale/calibrator established.
Also re the ABC-19 test, read the RNS', MIK.....they explicitly state that the ABC-19 antibody test could be used for patient stratification in overburdened healthcare settings overseas - far larger market space than the UK my friend.
Why not try looking for the opportunity in something for a change, rather than the negatives all the time?
Or MB.....they do with the antibody testing what they are already doing with the LF antigen test; they make them available at a local town hall/sports centre/clinic locally, where you can go in, register, still test yourself and get the result in 20-30 minutes.
Course you sold at £1.15 MIKODX . And i suppose you bought at the bottom . I have been here since april and never got a quote to sell at £1.15 even though people were buying at £1.26.
Dibs wow are you still here picking holes....
Please tell me how they can announce a contract value and volume? How can they predict the sales over a 3 year period of a new product in an ever evolving market?
The government have a reluctance to use LFT for antibody testing for home use due to the lack of control with results capture. This solves that problem. To have the approval for home collection and post to a lab opens up many opportunities, and it doesn't use up LFT manufacturing capacity.
This as a lot of potential in giving people convenience of home collection with the confidence of lab analysis. When you link in immunity passports and certification further down the line, this can play a key role. Notice on the UK Gov antibody tenders now, they mention testing kits in the £100m tender, not specifically lateral flow.
Omega have positioned themselves very well to adapt to testing demands and preferences. Not reliant on a single test or type of test. Covid is also a blueprint for diagnostics long term, so opens up longer term opportunities.